Login / Signup
Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
Muhammed Osman Corbali
Ahmet Emre Eskazan
Published in:
Future oncology (London, England) (2020)
Keyphrases
</>
acute myeloid leukemia
acute lymphoblastic leukemia
diffuse large b cell lymphoma
multiple myeloma
hodgkin lymphoma
combination therapy
replacement therapy